Co-enrolment of participants into multiple cancer trials: benefits and challenges by Cafferty, F et al.
lable at ScienceDirect
Clinical Oncology 29 (2017) e126ee133Contents lists avaiClinical Oncology
journal homepage: www.cl in icaloncologyonl ine.netOverviewCo-enrolment of Participants into Multiple Cancer Trials:
Beneﬁts and Challenges
F.H. Cafferty *, C. Coyle *, S. Rowley *, L. Berkman y, M. MacKensie z, R.E. Langley *
*MRC Clinical Trials Unit at UCL, London, UK
yNCRI Consumer Liaison Group, London, UK
z Independent Cancer Patient Voices, London, UKReceived 27 October 2016; received in revised form 14 February 2017; accepted 16 February 2017
Abstract
Opportunities to enter patients into more than one clinical trial are not routinely considered in cancer research and experiences with co-enrolment are rarely
reported. Potential beneﬁts of allowing appropriate co-enrolment have been identiﬁed in other settings but there is a lack of evidence base or guidance to
inform these decisions in oncology. Here, we discuss the beneﬁts and challenges associated with co-enrolment based on experiences in the Add-Aspirin trial e a
large, multicentre trial recruiting across a number of tumour types, where opportunities to co-enrol patients have been proactively explored and managed. The
potential beneﬁts of co-enrolment include: improving recruitment feasibility; increased opportunities for patients to participate in trials; and collection of
robust data on combinations of interventions, which will ensure the ongoing relevance of individual trials and provide more cohesive evidence to guide the
management of future patients. There are a number of perceived barriers to co-enrolment in terms of scientiﬁc, safety and ethical issues, which warrant
consideration on a trial-by-trial basis. In many cases, any potential effect on the results of the trials will be negligible e limited by a number of factors, including
the overlap in trial cohorts. Participant representatives stress the importance of autonomy to decide about trial enrolment, providing a compelling argument for
offering co-enrolment where there are multiple trials that are relevant to a patient and no concerns regarding safety or the integrity of the trials. A number of
measures are proposed for managing and monitoring co-enrolment. Ensuring acceptability to (potential) participants is paramount. Opportunities to enter
patients into more than one cancer trial should be considered more routinely. Where planned and managed appropriately, co-enrolment can offer a number of
beneﬁts in terms of both scientiﬁc value and efﬁciency of study conduct, and will increase the opportunities for patients to participate in, and beneﬁt from,
clinical research.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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org/licenses/by/4.0/).reported or discussed in oncology literature. As such, co-
enrolment policies may be speciﬁed in the trial protocol
or decisions made by an institute or recruiting investigator,
without a clear rationale or evidence base. With a lack of
guidance or consensus on when co-enrolment is appro-
priate, it is unsurprising that the decision not to co-enrol
may be seen as the safe option.
Recent trends in oncology research e such as the use of
longer term, maintenance therapies and evaluation of
repurposed agents (whose use alongside other treatments
may already be well documented) e as well as the ever-
increasing number of trials competing for the same pa-
tients, mean that co-enrolment is becoming more relevant.
More routine consideration of opportunities to enter pa-
tients into multiple trials is warranted.is is an open access article under the CC BY license (http://creativecommons.
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settings e particularly those where trial recruitment is
challenging and/or there aremany (large) competing trialse
including resuscitation [1], critical care [2e4] (including
neonatal [5] and paediatric [6] settings) and peri-natal
research [7]. Here, co-enrolment offers the opportunity to
maximise use of the patient population and increase the
speed and efﬁciency of research delivery. In settings such as
HIV [8] and anaesthesia [9], where large, pragmatic trials are
common and/or participants might be receiving several
other medications, co-enrolment may also provide impor-
tant data on drug interactions.
Across different settings, researchers report barriers to
co-enrolment and, frequently, a lack of (universal) support
from the research community or ethics committees [2,6,9].
Common barriers range from ethical and scientiﬁc consid-
erations to safety concerns [1e3,6,7,9]. The need for further
reporting of co-enrolment and more research on this topic,
is noted [4,7,10].
The potential beneﬁts of co-enrolment, as well as
possible barriers, are relevant in oncology trials andwarrant
further exploration. Here, we report our experiences with
exploring and managing co-enrolment opportunities
within a large, multicentre oncology trial.The Add-Aspirin Trial
The Add-Aspirin trial is a randomised controlled trial
(RCT) assessing whether regular aspirin use after curative
treatment for an early stage tumour can prevent recurrence
and prolong survival (Figure 1) [11e13]. The intervention is
being tested in four tumour types (breast, colorectal, gastro-
oesophageal and prostate) by means of parallel cohorts.Fig 1. The Add-APatients enrol following potentially curative therapy e this
incorporates a range of treatment pathways for each
tumour site, including surgery with any appropriate (neo-)
adjuvant therapies, radical chemoradiation (oesophageal)
and radical radiotherapy (prostate). Participants are rand-
omised to daily aspirin 100 mg, 300 mg or placebo. The trial
is recruiting across the UK, and will also open in India, with
a target of approximately 10 000 participants.
Co-enrolment may be relevant to patients entering Add-
Aspirin subsequent to enrolling in a primary therapy trial
and may also arise at the time of recurrence during partic-
ipation in Add-Aspirin. A proactive approach to exploring
co-enrolment opportunities with other trial teams has been
adopted to agreewhen thismight be appropriate and how it
can be facilitated and managed within the ongoing trials.Beneﬁts of Co-enrolment
Co-enrolment is particularly relevant in Add-Aspirin as
the intervention is being given after initial treatment, so
participants from trials of primary therapies represent a
signiﬁcant proportion of the eligible population. However,
the potential advantages of co-enrolment apply more
widely to multicentre oncology RCTs e particularly prag-
matic trials e as a number of different interventions will be
relevant to a patient over the course of their disease and
treatment. Allowing appropriate co-enrolment improves
the efﬁciency of recruitment, helping to ensure the feasi-
bility of trials running concurrently, and maximises op-
portunities for patients to participate in, and beneﬁt from,
clinical research.
A further advantage is the opportunity to assess trial
interventions alongside one another, helping to ensure thespirin trial.
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potentially both be given to a patient in future practice,
collection of information on their combined use will be
valuable for establishing the importance of each one,
providing more cohesive evidence to inform the manage-
ment of future patients.
There are, of course, potential concerns in allowing pa-
tients to enrol in multiple RCTs. In what follows, we
consider the scientiﬁc, safety and ethical issues.Impact on Trial Results
A principle concern with co-enrolment is the potential
effect on the results of the trials, particularly when they are
evaluating a common outcome measure. We would argue
that, although this issue deserves careful consideration, in
many cases any effect will probably be negligible, and
should not generally be a prohibitive factor.
In Add-Aspirin, due to the timing of the intervention, we
are commonly considering the case of sequential co-
enrolment e patients entering Add-Aspirin having previ-
ously enrolled in another trial. This would also be the case if
considering trials of second- or third-line treatment after
relapse in patients who had participated in a primary
therapy trial. Here, assuming there is no interaction be-
tween the interventions, there is no concern about an effect
on the results of the second trial (Add-Aspirin). However,
there is the potential for an effect on the results of the ﬁrst
trial if participants from the different arms enter Add-
Aspirin at different rates. This may occur because patients
from one arm of the trial are either more likely to be eligible
(for example, patients need to be disease-free, which may
be more likely in the experimental arm of the ﬁrst trial) or
they are more likely to be willing to participate (forFig 2. Factors affecting the potential effect of co-enrolment onexample, if one arm of the ﬁrst trial has a shorter or less
toxic treatment). In these scenarios, if aspirin is effective, it
will have a differential effect in the trial arms of the ﬁrst
trial with the potential to affect the power. Although
stratiﬁcationwithin Add-Aspirin for the trial arm in the ﬁrst
trial will help to ensure balance in terms of those in-
dividuals entering Add-Aspirin, there may still be an overall
imbalance in terms of aspirin allocation between the arms
of the ﬁrst trial when those who did not join Add-Aspirin
are also considered.
We have estimated the magnitude of any potential effect
in different scenarios and found that it is generally limited
by a number of factors (Figure 2). Statistical modelling, us-
ing ranges of assumptions, suggests that any effect on the
power of the ﬁrst trial will probably be small. Table A1 (web
appendix) provides an example showing selected models,
including some felt to illustrate the largest plausible effect.
Signiﬁcant effects were only anticipated with relatively
large (improbable) differences in participation rates and
were further increasedwhen therewere unexpectedly large
effects of aspirin. Co-enrolling trials could be monitored for
this unlikely set of circumstances, with the potential to stop
co-enrolment if there were concerns. Our models do not
consider the potential effect of aspirin use outside the Add-
Aspirin trial (participants from the ﬁrst trial already taking
aspirin), which may further limit any effect. Similar limiting
factors are noted in other settings [9]. However, this should
be carefully considered on a trial-by-trial basis, before any
co-enrolment, and subsequently monitored.Interaction Effects
Our modelling has generally assumed that there are no
interaction effects between trial interventions e this ispower. *Intervention being evaluated in the second trial.
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Aspirin. However, others argue that the potential for an
interaction between two trial interventions should not
necessarily prohibit co-enrolment and, in fact, can facilitate
evaluation of the interaction (particularly relevant where
interventions are already in use outside of the trials) [7e9].
The information gained from co-enrolled participants may
be insufﬁcient to formally establish if there is an interaction
but will be more robust data than would otherwise be
available [7e9]. Modelling based on pragmatic anaesthesia
trials suggested that a large detrimental effect on the power
of the ﬁrst trial would only be seenwith a large antagonistic
interaction, substantial co-enrolment and limited use of the
second trial intervention outside of the trial [9].
A factorial randomisation can be viewed as preferable to
co-enrolment between separate trials, butmay not always be
practical or sensiblee for example, if the combination of the
two interventions is only relevant to a small subgroup or, as
with Add-Aspirin, one intervention is given at a later time,
dictating the most appropriate timing for randomisation.
Furthermore, the (statistical) advantages of a factorial design,
compared with co-enrolment, may not be great [4,8,9]. The
potential for loss of power for assessing one intervention, in
the presence of the other, may still exist, and factorial trials
are not normally powered to detect interactions.Safety Considerations
There may, of course, be safety concerns with patients
receiving interventions from two different trials. This will be
highly dependent on the interventions. If there are concerns
or a high degree of uncertainty about toxicity risks then co-
enrolment will probably be avoided. However, in a trial of a
marketed product or intervention that is already in use in
normal practice, co-enrolmentwill bemore acceptable [9]. In
Add-Aspirin, participants receive low-dose aspirinorplacebo.
In most of the primary treatment trials where co-enrolment
may be relevant, there will already be patients taking
aspirin alongside the trial intervention. Allowing participants
to subsequently enrol in Add-Aspirin may facilitate the
collection of more robust data on the use of aspirin alongside
(or following) the intervention to guide future practice.
Concerns regarding liability, in the event of a personal
injury claim beingmade by a trial participantwho is enrolled
in multiple trials, have been raised as a potential barrier to
co-enrolment, but we do not believe this is justiﬁed. Existing
indemnity arrangements for each trial should sufﬁce.The Participant’s Perspective
In addition to potential scientiﬁc beneﬁts, allowing trial
co-enrolment, where appropriate, will maximise opportu-
nities for patients to participate in research. However, the
approach must be both ethically sound and acceptable to
(potential) participants e these are perhaps the most com-
plex issues surrounding co-enrolment and there is currently
a lack of guidance or evidence in the literature to inform this.In our discussions with other trial teams regarding co-
enrolment, some researchers have expressed concerns that
asking patients to join more than one trial may over-burden
them, a view that has proved to be a barrier in other settings
[6]. The participant representatives on the Add-Aspirin Trial
Management Group (co-authors on this paper), have been
strong advocates of co-enrolment from the outset, and
would argue that there is an opposing ethical obligation to
provide all of the information required to allow an individual
to decide for themselves about joining any trial that is
relevant to them. Not approaching a patient to participate in
a trial that they could be eligible for because they are already
enrolled in another study would be denying them an op-
portunity. Similar conclusions were reached in a review of
co-enrolment considerations in the anaesthesia setting, with
the authors feeling that preventing patients from autono-
mously co-enrolling is difﬁcult to justify ethically [9].
A survey of patients in a research-active breast cancer
unit provides evidence to support these views [14]: three-
quarters of respondents (37/50, 74%) would have consid-
ered entering more than one study if adequate written in-
formation was provided. Most (32/50, 64%) did not believe
that participation in clinical research should be restricted to
amaximumnumber of studiese and, of thosewho did, only
two indicated that it should be limited to a single study.
Furthermore, two-thirds of respondent (34/50, 68%) did not
think that involvement in more than one study was a sig-
niﬁcant burden.
A similar survey of 50 families approached aboutmultiple
(up to six) clinical trials in a neonatal intensive care unit
suggested similar attitudes (despite the setting, where the
potential to over-burden families may be even more of a
concern) [5]: three-quarters (74%) of parents indicated that
theywould enrol their baby into two ormore studies; almost
all (98%) felt they wanted to make the decisions about study
enrolment themselves, rather than a clinician deciding.
Although the data from these studies are reassuring, they
are limited and may reﬂect the views of select groups of
individuals. Further exploration with patients and with
groups representing patient and public involvement (PPI) is
warranted.Measures to Increase Acceptability
Comments from respondents in the breast unit study
emphasised the importance of individual choice as well as
concerns around extra hospital visits interfering with
normal life [14]. These are areas that need to be addressed
in trials where co-enrolment is deemed appropriate.
Researchers have an obligation to carefully consider the
timing of approaching potential participants about each
trial, ensuring that the information provided (not only
about the individual trials but also about the implications of
joining more than one) is clear and there is sufﬁcient op-
portunity for questions. In the paediatric intensive care
setting, Harron et al. [6] advocated careful development and
piloting of a strategy for the whole consent process when
multiple studies may be available to an individual.
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tween follow-up schedules for two trials where co-
enrolment is possible in order to minimise the number
of additional hospital visits and assessments/tests
compared with standard care. Ideally, this would be
planned at the design stage. Where co-enrolment de-
cisions may be made during the trial, allowing some
ﬂexibility in schedules will work towards this aim e
enabling research nurses to plan clinic visits that will meet
the requirements of both trial schedules. In Add-Aspirin,
follow-up schedules have been planned to largely align
with standard care e and this will be the case with many
pragmatic trials. Additionally, there is some ﬂexibility
regarding the timing of assessments.
In the above considerations, engagement with and input
from participant representatives and PPI groups is vital to
ensure that the approach is acceptable to participants and
will not lead to unnecessary additional burden.Ethical Approvals
Some researchers report resistance from ethics com-
mittees as an obstacle to allowing individuals to enter
multiple trials [2,14]. This has not been the experience in
Add-Aspirin e the potential for participants from multipleTable 1
Proposed measures for trial teams managing co-enrolment within a ra
Proposed measure
Design Identify trials where co-enrolment may be considere
Develop appropriate consent process*
Ensure compatibility of follow-up schedules, allowing
ﬂexibility where possible/appropriate*
Provide guidance on co-enrolment in the protocol (a
trial website/other documents as appropriate)
Consider stratifying by treatment arm in the ﬁrst tria
the randomisation algorithm for the second trial (wh
signiﬁcant overlap is expected)
Conduct Implement eligibility checks around co-enrolment at
entry
Consider implementation of screening logs
Monitoring Collect and regularly review co-enrolment informatio
including treatment allocation in the other trial, on c
report forms
Establish agreements to share information between d
monitoring committees (blinded trials)
* In discussion with participant representatives and/or patient and p
y This will not ensure balance overall if participants from the differen
rates. Thus, careful monitoring is still required.primary treatment trials to enrol in Add-Aspirin has been
written into the trial protocol from the outset, and was not
raised as an issue by the ethics committee who approved
the study, nor by the regulators nor funders of the trial.
Thus, there is perhaps a need for a more consistent
approach to trial co-enrolment by research ethics commit-
tees. We would suggest that co-enrolment, where appro-
priate, should generally be supported in order to allow
potential participants the autonomy to decide about
enrolling in any trial that is relevant to them. However, this
should be on the provisos that: the informed consent pro-
cess and trial follow-up schedules have been carefully
considered; the safety of receiving both trial interventions
has been deemed acceptable; and any other appropriate
measures are in place to minimise any extra burden on
participants as far as possible.
The potential scientiﬁc advantages of allowing co-
enrolment (where appropriate), in terms of increasing
both the value and efﬁciency of the research, provide
further ethical justiﬁcation for the approach. Myles et al. [9]
argue that an important ethical consideration in research
planning is the efﬁcient conduct of studies and fairer allo-
cation of resources for research, and that allowing co-
enrolment can contribute to this aim. Furthermore, if two
interventions being evaluated in trials might potentially
both be given to a patient in future practice, there isndomised controlled trial
Purpose
d Assess potential impact and agree where co-enrolment is
appropriate in advance
Ensure that being approached about multiple studies will
be acceptable to patients
Minimise extra visits/assessments, ensuring that
participation in multiple studies will be acceptable to
patients
nd Ensure only appropriate co-enrolment takes place and
follows the strategy developed for consent and follow-up
l in
ere
Ensure treatment allocation in the second trial is balanced
(in terms of those individuals who enter the second trial)y
Ensure only appropriate co-enrolment takes place
Identify any recruitment issues as a result of co-
enrolment decisions or any barriers to co-enrolment
n,
ase
Active monitoring with the potential to take action e by
capping recruitment from one arm, for example e if a
large imbalance occurs (although this is unlikely)
ata It may be appropriate for monitoring to be carried out by
data monitoring committees in the case of blinded trials
ublic involvement groups.
t treatment arms of the ﬁrst trial enter the second trial at different
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formation on the combined use of the therapies in order to
establish the importance and safety of each one in the
context of the other, and provide more cohesive evidence to
inform the management of future patients [7].Managing Co-enrolment
Where co-enrolment to multiple oncology RCTs is
permitted, given the issues outlined here, it requires careful
management and monitoring. We propose a number of
measures (Table 1).
A precedent for designing and conducting RCTs to facil-
itate co-enrolment has been set in the HIV ﬁeld (Terry Beirn
Community Programs for Clinical Research on AIDS; CPCRA)
[8]. Measures include shared data collection forms; stand-
ardised deﬁnitions and criteria for assessing and reporting
outcomes and adverse events; a single, common follow-up
schedule; and an analysis approach that explores drug
interactions.Discussion
For the vast majority of trials where co-enrolment with
Add-Aspirin has been considered, we have found that it is
likely to be acceptable both in terms of the safety of par-
ticipants and maintaining the integrity of trial results. As
such, the importance of giving individuals the autonomy to
make their own decisions about trial participation provides
a compelling ethical argument for allowing co-enrolment,
wherever appropriate, providing that it is done in a way
that will be acceptable to participants. We have encoun-
tered a number of perceived barriers that may not be well-
founded and there is a need for further evidence to promote
greater understanding about the potential impact of co-
enrolment.
The beneﬁts of co-enrolment alignwith the original aims
in establishing the National Cancer Research Network,
which include improving the co-ordination and quality of
research, widening participation, increasing the numbers of
patients involved and speeding up the delivery of research
for the ultimate beneﬁt to patients [15]. As such, we suggest
it should be routinely considered by the associated clinical
studies groups in reviewing trial portfolios, with the aim of
maximising co-enrolment opportunities.
The implications of individuals participating in more
than one trial are multifactorial and should be carefully
considered on a trial-by-trial basis. Evidence relating to
acceptability is limited, and more research is needed.
However, as it is probably highly dependent on the patient
group and the speciﬁc trials under consideration, engage-
ment with relevant PPI groups and representatives, from
the planning stage and throughout the trial, is crucial to
ensure that the appropriate measures are in place. There is
an onus on the trial teams to evaluate acceptability and any
potential (scientiﬁc) consequences in advance, and tomonitor co-enrolment closely throughout the trial, man-
aging any issues appropriately with a pre-deﬁned strategy.
Trial protocols should not enforce a complete ban on co-
enrolment without sound justiﬁcation.
Much could be learnt from the CPCRA programme,
where efforts to facilitate co-enrolment led to a quarter
(22.5%) of patients from six RCTs entering more than one
trial [8]. The programme was developed by a single
research group e a high degree of co-operation and strong
lines of communication would be required to achieve
similar where trials are being conducted by different
groups. In other settings, the establishment of co-
enrolment policies or consensus guidelines has been
advocated [4,8,10]. This could be a way forward in
oncology research.
A more considered and co-operative approach to co-
enrolment will not only beneﬁt individual trials, but
may contribute to an evidence base showing the extent of
co-enrolment and any observed impact or issues. Limited
reports from other settings have not indicated any nega-
tive impact [3,6]. Based on the experiences in Add-
Aspirin, we hope that such data might ultimately reas-
sure researchers of the beneﬁts of allowing participants to
co-enrol where there are multiple oncology trials that are
relevant to them. Add-Aspirin opened in October 2015
and, to date, the possibility of co-enrolling relevant pa-
tients has been agreed for 40 other trials, across the four
tumour types. The number of participants who have been
co-enrolled remains small at this early stage of
recruitment.Conclusions
Opportunities for co-enrolment of participants into
multiple cancer trials should be more routinely considered.
Where planned and managed appropriately, co-enrolment
can offer a number of beneﬁts in terms of both the scien-
tiﬁc value and efﬁciency of study conduct, and will increase
the opportunities for patients to participate in, and beneﬁt
from, clinical research.Acknowledgments
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Example power calculations to assess the potential impact of co-enrolment
Modelling assumptions Estimated impact on trial X













Control Intervention Control Intervention Difference
Trial X result is positive (5 year survival 55% control versus 45% intervention) in the absence of co-enrolment
6% 10% 10% 45.4% 55.4% 10.0% 79.9% 2 (1 month)
20% 20% 45.8% 55.8% 10.0% 79.9% 3 (1 month)
30% 30% 46.2% 56.2% 10.0% 79.8% 5 (1 month)
10% 15% 45.4% 55.6% 10.2% 81.5% e
10% 20% 45.4% 55.8% 10.4% 82.9% e
15% 30% 45.6% 56.2% 10.6% 84.3% e
15% 10% 45.6% 55.4% 9.8% 78.3% 44 (3 months)
20% 10% 45.8% 55.4% 9.6% 76.6% 89 (5 months)
30% 15% 46.2% 55.6% 9.4% 74.8% 138 (8 months)
10% 10% 10% 45.7% 55.7% 10.0% 79.9% 3 (1 month)
20% 20% 46.3% 56.3% 10.0% 79.8% 5 (1 month)
30% 30% 47.0% 57.0% 10.0% 79.8% 7 (1 month)
10% 15% 45.7% 56.0% 10.3% 82.4% e
10% 20% 45.7% 56.3% 10.7% 84.7% e
15% 30% 46.0% 57.0% 11.0% 86.8% e
15% 10% 46.0% 55.7% 9.7% 77.2% 75 (5 months)
20% 10% 46.3% 55.7% 9.3% 74.2% 154 (9 months)
30% 15% 47.0% 56.0% 9.0% 71.1% 244 (15 months)
Trial X result is negative (5 year survival 45% in both arms) in the absence of co-enrolment
6% 10% 10% 45.4% 45.4% 0.0%
20% 20% 45.8% 45.8% 0.0%
30% 30% 46.2% 46.2% 0.0%
10% 15% 45.4% 45.6% 0.2%
10% 20% 45.4% 45.8% 0.4%
15% 30% 45.6% 46.2% 0.6%
15% 10% 45.6% 45.4% 0.2%
20% 10% 45.8% 45.4% 0.4%
30% 15% 46.2% 45.6% 0.6%
Trial X result is negative (5 year survival 45% in both arms) in the absence of co-enrolment
10% 10% 10% 45.7% 45.7% 0.0%
20% 20% 46.3% 46.3% 0.0%
30% 30% 47.0% 47.0% 0.0%
10% 15% 45.7% 46.0% 0.3%
10% 20% 45.7% 46.3% 0.7%
15% 30% 46.0% 47.0% 1.0%
15% 10% 46.0% 45.7% 0.3%
20% 10% 46.3% 45.7% 0.7%
30% 15% 47.0% 46.0% 1.0%
The table illustrates the potential impact of co-enrolment into Add-Aspirin on the power of a hypothetical study, trial X. Selected results are
shown from models performed under a range of assumptions about the factors listed in Figure 2, including scenarios felt to illustrate the
largest plausible impact on power.
Trial X: A hypothetical two-arm superiority randomised controlled trial of a new peri-operative chemotherapy regimen versus standard in
gastro-oesophageal patients. Designed with 80% power to detect a 10% improvement (from 45% to 55%) in survival at 5 years, requiring 500
patients per arm. Patients who are disease free at the end of treatment may become eligible for Add-Aspirin.
* A 6% survival beneﬁt at 5 years is hypothesised in Add-Aspirin (gastro-oesophageal). Models are repeated for larger beneﬁts to illustrate
potential effects on power.
y A range of participation rates are used to assess potential impacte actual rates are unlikely to reach 30% (limited by overlap in recruiting
centres and recruitment periods, as well as trial X participants being ineligible or unwilling to participate in Add-Aspirin). Differences in
rates between arms are also unlikely to be as large as illustrated here.
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